Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | CASP3 | P42574 | 2/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23061476 | 0.85 | HTT (0.37) | RAB9AHTTNPC1CASP3SENP8 | |
| SCHEMBL22651234 | 0.84 | RAB9A (0.38) | RAB9AHTTNPC1CASP3SENP8 | |
| SCHEMBL25657151 | 0.84 | NPC1 (0.39) | RAB9AHTTNPC1CASP3SENP8 | |
| SCHEMBL24496166 | 0.84 | KCNH2 (0.36) | RAB9AHTTNPC1CASP3SENP8 | |
| SCHEMBL24604442 | 0.82 | RAB9A (0.36) | RAB9AHTTNPC1CASP3SENP8 | |
| SCHEMBL22651406 | 0.82 | ELANE (0.38) | RAB9AHTTNPC1CASP3SENP8 | |
| SCHEMBL23698605 | 0.81 | HTT (0.35) | RAB9AHTTNPC1CASP3SENP8 | |
| SCHEMBL17485425 | 0.80 | RAB9A (0.39) | RAB9AHTTNPC1CASP3SENP8 | |
| SCHEMBL23084629 | 0.79 | CHRM2 (0.34) | RAB9AHTTNPC1CASP3SENP8 | |
| SCHEMBL22650959 | 0.78 | NPC1 (0.36) | RAB9AHTTNPC1CASP3SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | STING1, CGAS, IFNAR1 | RAB9A 2212/4885HTT 4842/4885NPC1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.